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ABSTRACT
Objective: The relative risk of coronary heart disease in diabetic patients is more than in non-diabetic population. The present study was undertaken 
to explore the cardioprotective effect of Naringin on ischemia-reperfusion injury in the diabetic model of rat.
Methods: Adult Wistar rats (either sex) divided into six groups. Diabetes was induced by 5 weeks combine exposure to a high-fat diet with a low dose of 
streptozotocin (30 mg/kg i.p.), administered on the 1st day of starting of the 5th week. Naringin treatment 25 mg/kg and 50 mg/kg was given simultaneously 
for 5 weeks. On the 36th day, the study animals were subjected to induction myocardial ischemia-reperfusion injury induced by the ligation of the left anterior 
descending coronary artery ligation in anesthetizing rat. Serum glucose level and cholesterol level measured before performing of ischemic reperfusion. 
After reperfusion injury, the animals were sacrificed and estimate change in the heart in the course of biochemical alterations, in creatine kinase-muscle/
brain (CK-MB) and lactate dehydrogenase, lipid peroxidation (LPO), glutathione (GSH), superoxide dismutase (SOD) and infarct size in the heart.
Results and Conclusion: Naringin treatment significantly reduced the body weight, blood glucose, cholesterol, cardiac injury biomarkers, and LPO 
level and increased in antioxidant (GSH and SOD) level and also significantly increased in mean arterial pressure heart rate, reduced the myocardial 
infarction size. The present study concludes that Naringin 50 mg/kg being more prominent action to reduce the cardiotoxicity risk in ischemia-
reperfusion injury state and increases myocardial susceptibility through having more prominent antioxidant potential properties.
Keywords: Diabetes, Ischemia-reperfusion injury, Naringin.
INTRODUCTION
Cardiovascular diseases are the major cause of death and disability 
in people with diabetic patients [1]. The mortality rate of the 
diabetic patient after coronary bypass grafting is about twice 
that of the non-diabetic patient [2]. The diabetic heart is more 
prone to develop ventricular tachyarrhythmia and high-degree 
atrioventricular block [3]. Diabetes mellitus increases susceptibility 
to ischemia-reperfusion injury and also modifies myocardial 
responses to ischemic conditioning strategies by disruption of 
intracellular signaling responsible for the enhancement of resistance 
to cell death [4,5]. Endothelial dysfunction has received increasing 
attention as a potential contributor to the development of vascular 
disease in diabetes mellitus [3]. It caused the activation of major 
molecular signaling mechanisms protein kinase C, hexosamine flux, 
polyol pathway flux, and increased advanced glycation end product 
formation [6]. The diabetic heart is more sensitive for the coronary 
heart disease due to decreased glycolysis and alters the sarcolemmal 
Na+/H+ and Na+/Ca2+ exchange activities and diabetic heart also 
increases the free fatty acid and an inflammatory mediator which 
is responsible for the cell damage and death during the ischemia 
condition [7]. Susceptibility to coronary heart disease is also increased 
due to the altered cardioprotective mechanism. An in vivo small rodent 
model for myocardial ischemia-reperfusion injury-induced damage in 
diabetes mellitus in which administration of high-fat diet (HFD) with 
a low dose of streptozotocin (STZ) and surgical occlusion of coronary 
artery followed by reperfusion more closely to the real clinical setting.
A therapeutic approach such as antihyperglycemic, antihyperlipidemic, 
and antioxidant compound can be beneficial in the prevention of 
cardiovascular complication associated with diabetes mellitus. 
Flavonoids are an important group of secondary metabolites and a 
source of bioactive compounds in plants. It was first discovered in the 
flowers of grapefruit. Naringin is major flavanone glycoside obtained 
from tomatoes, grapefruits, and many other citrus fruits, it presents 
in grape juice up to concentrations of 800 mg/L. It experimentally 
documented to possess numerous biological properties such as 
antioxidant, anti-inflammatory, and antiapoptotic activities [8]. It 
is potential to be a useful dietary supplement in the management 
of the signs of metabolic syndrome. The molecular mechanism 
involved in the activation of the adenosine monophosphate (AMP) 
kinase, peroxisome proliferator-activated receptor-γ, suppressed 
fatty acid synthesis, and lowering blood glucose and cholesterol 
concentrations [9]. Naringin markedly suppressed HG-triggered 
cytotoxicity and apoptosis and it was suggested that contributed to 
cardioprotection by attenuating mitochondrial dysfunction. Naringin 
is a potent antioxidant effect by activation of novel antioxidant 
defense mechanism. It can play an important role in the management 
of hyperglycemia [8]. It also used in the treatment of atherosclerosis 
through inhibition of the HMG-CoA reductase, the release of 
tumor necrosis factor (TNF-α), and nuclear factor-kβ activation 
and protected against the endotoxic shock and blocked the lethal 
shock [10]. Naringin protects against lipopolysaccharide-induced 
acute lung injury in mice through suppression of iNOS activity, TNF-α 
secretion, and myeloperoxidase [11]. Experimental studies reported 
the protective effect of Naringin against ischemia-reperfusion-
induced injury in rat [12].
On behalf of previous reports, Naringin could be a less toxic and more 
selective therapeutic approach for the treatment of diabetic-induced 
cardiovascular complications. The aim of this study was to assess 
whether treatment with the Naringin glycoside can prevent or mitigate 
the changes on infarct size, hemodynamic, and biochemical alterations 
in ischemia-reperfusion injury under diabetic state and its deleterious 
effects on cardiovascular disease.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i3.30105
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METHODS
Drugs and chemicals
Naringin, STZ, glutathione (GSH), and triphenyltetrazolium chloride 
(TTC) were purchased from Sisco Research Laboratories. Thiobarbituric 
acid (TBA) and dithiobis-2-nitrobenzoic acid were purchased from 
Himedia, Mumbai. Cholesterol kit was purchased from Erba Diagnostic 
and glucose, creatine kinase-muscle/brain (CK-MB), and lactate 
dehydrogenase (LDH) kits purchased from Reckon Diagnostic.
Study animals
The research protocol of this study has been approved by the 
Institutional Animal Ethics committee (IAEC) vide approval No-ASCB/
IAEC/10/17/119. Adult Wistar rats (either sex), weighing between 200 
and 250 g, were procured from registered breeder.
Experimental design
Experimental Groups-1 and 2: Rats were administered 0.9% normal 
saline (p.o.) with normal chow diet and HFD was administered for 
5 weeks, on the 36th day, rats were subjected to thoracotomy and 
thread passed beneath the left anterior decent coronary artery 
(LADCA) but no ligation performed, respectively. Group-3: Rats were 
administered 0.9% normal saline (p.o.) with HFD was administered for 
5 weeks and STZ was administered on starting of the 5th week, on the 
36th day, rats were to LADCA ligation for 30 min and reperfusion for 
60 min to induce myocardial I-R injury. Groups - 4 and 5: Rats were 
administered Naringin 25 and 50 mg/kg, p.o. [9], respectively, with HFD 
was administered for 5 weeks and STZ was administered on starting 
of the 5th week, on the 36th day, rats were to LADCA ligation for 30 min 
and reperfusion for 60 min to induce myocardial I-R injury. Group-6: 
Rats were administered glibenclamide 20 mg/kg, p.o. with HFD was 
administered for 5 weeks and STZ was administered on starting of the 
5th week, on the 36th day, rats were to LADCA ligation for 30 min and 
reperfusion for 60 min to induce myocardial I-R injury.
Induction of diabetes
Diabetes was induced by combining exposure to an HFD with low dose 
of STZ. Rats were fed with high-fat containing diet (HFD) for 5 weeks 
and STZ was administered on starting of the 5th week. Composition of 
HFD (normal chow diet 67%, sucrose 20%, pig lard 10%, and custard 
powder 2.5%) STZ was administered at a dose 30 mg/kg, i.p. was 
prepared by freshly dissolved in 0.1 M citrate buffer, pH 4.5. HFD-
induced insulin resistance and STZ destroyed a portion of pancreatic 
β-cell. The plasma glucose was measured after 72 h of STZ injection (the 
blood samples were collected through retro-orbital plexus technique 
using capillary glass tube). Animal showing blood glucose more than 
250 mg/dL was considered as diabetic [13].
Induction of myocardial ischemic reperfusion injury
On the 36th day, after induction of diabetes in rat was subjected to 
induction of myocardial I-R. Rat was anesthetized with urethane at 
dose of 1.5 g/kg, i.p. and body temperature was maintained at 37°C 
using heating pad throughout the experiment. Neck was opened 
and tracheotomy and left thoracotomy were performed at the fifth 
intercostals space using rib cuter and retractor. Pericardium was 
opened to expose the heart and a 5/0 surgical suture attached to 
a 16 mm needle (circle cutting) was quickly placed under the left 
coronary artery. The animal was then stabilized for 10–15 min before 
the left coronary artery ligation. The left coronary artery was ligated 
2–3 mm from its origin between the pulmonary artery cones and left 
atrium with needle-suture by pressing the polyethylene tubing against 
the ventricular wall. The animal then underwent 30 min of ischemia 
and reperfusion for a period of 60 min [13].
Hemodynamic parameters measurement
Separation of carotid artery attached with vagus nerve was done 
by pointed curve forceps, and then, carotid artery cannulated with 
polyethylene tube (internal diameter 0.30 mm and outer diameter 
0.40 mm) attached to a three-way cannula. The cannula was 
heparinized (Heparin 300 IU/ml) and connected to power lab 4/30 
(AD instruments, NSW, Australia) system using a pressure transducer 
for the measurement of hemodynamic parameters.
Assessment of blood glucose, cholesterol, CKMB, and LDH level
Blood sample was collected from the rats at end of the experimentation. 
The blood was collected by puncturing retro-orbital plexus under 
chloroform anesthesia and collected in Eppendorf tubes (1.5 ml) 
and centrifuged (4000 rpm for 10 min) for the estimation of glucose 
and cholesterol using assay kits on autoanalyzer (Microlab 300). The 
2nd time blood was collected from the carotid artery after the myocardial 
reperfusion procedure and prepare sample as similar above-mentioned 
method, and estimation of LDH and CK-MB by assay kits. 
Evaluation of myocardial infarct size
The myocardial infarct size measured using TTC staining method. The 
heart was transversely cut to obtain slices no >0.1 cm in thickness. The 
heart slices were placed in the glass dish containing pre-warmed (1%) 
TTC in phosphate buffer solution (the 1% TTC powder diluted in a 
phosphate buffer). The image of TTC slices was captured with a digital 
camera and analyzed by Image J software [14].
Studies of rat heart parameters
Animal was sacrificed and heart tissue was removed, washed with 
the chilled isotonic saline, and dried with filter paper. After this 
heart was diced and homogenized in 0.05 chilled cold phosphate 
buffers. After centrifugation, supernatant was used for the analysis 
of antioxidant enzymes TBARS [15], GSH [16], and superoxide 
dismutase (SOD) [17].
Statistical analysis
All the results are expressed as mean±standard error of mean (SEM). 
The data of all the groups were analyzed by one-way ANOVA followed 
by Tukey’s multiple comparison tests using software GraphPad Prism. 
A value of p<0.05 was considered to be statistically significant.
RESULTS
Effect of Naringin on body weight
Diabetic control rats show significant (p<0.05) increase in body weight 
in the 1st and 5th weeks and significantly (p<0.001) gain in body weight 
2nd–4th weeks as compare to sham control groups. On treatment with 
Naringin (25 mg/kg), a significant (p<0.05) decreased in body weight 
in the 3rd and 5th weeks, as well as similar treatment significant (p<0.01) 
decreased but maintained body weight in final 4th week as compare to 
diabetic I-R rats. On treatment with Naringin (50 mg/kg), a significant 
(p<0.01) decreased but maintained body weight was observed in the 
1st week, further observe (p<0.001) over the duration of the 2nd–5th 
weeks as compared to diabetic IR rats. Treatment with the standard 
glibenclamide (20 mg/kg), a significant (p<0.05) decreased but 
maintained body weight was observed in the 1st week, further observe 
a decrease in body weight (p<0.001) over the duration of the 2nd–
5th weeks as compared to diabetic IR rats.
Following the injection of STZ (dose) on day 1 of the 5th week, decrease 
in body weight of diabetic control and diabetic IR rats was observed, but 
STZ (dose) administration did not alter body weight or weight gain in 
the Naringin (25 and 50 mg/kg) and glibenclamide (20 mg/kg) treated 
rats in final week as compared to diabetic IR rats (Fig. 1).
Effect of Naringin on water intake
Diabetic control rats show significant (p<0.001) increase in water 
intake over the duration of 5 weeks as compared to the sham control 
group. The water intake significant (p<0.05) reduces in Naringin 
(25 mg/kg) treated rats in the 1st and 3rd weeks and also significantly 
(p<0.01) increased in water intake at the 4th week, as well as similar 
treatment significant (p<0.001) decreased over the duration of the 
2nd and 5th weeks as compare to diabetic I-R rats. Naringin 50 mg/kg 
and glibenclamide 20 mg/kg treated rats show significant (p<0.001) 
increase in water intake over the duration of the 5th week as compared 
to diabetic I-R control rats (Fig. 2).
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Effect of Naringin on feed intake
Diabetic control rats show significant (p<0.05) increase in feed intake in 
the 2nd week and also increase (p<0.01) in feed intake over the duration 
of the 3rd and 5th weeks, as well as similar treatment significant (p<0.001) 
increase over the duration of the 4th week compare to sham control 
groups. On treatment with Naringin (50 mg/kg), a significant (p<0.05) 
decreased in feed intake over the duration of the 2nd and 5th weeks and 
also decreased (p<0.01) in the 3rd week, as well as significantly decreased 
(p<0.001) in the 4th week as compared to diabetic IR rats (Fig. 3).
Effect of Naringin on blood glucose and cholesterol level, CK-MB, 
and LDH
Blood glucose and cholesterol level were significant (p<0.001) increase 
in diabetic rats as compared to sham control group. Naringin (25 and 
50 mg/kg, p.o.) and glibenclamide (20 mg/kg, p.o.) treated rats show 
significant (p<0.001) decrease in glucose level, as compare to diabetic 
I-R control rats. Cholesterol level was significantly (p<0.001) decreased 
in Naringin-treated rats (25 and 50 mg/kg, p.o.), as compared to 
diabetic I-R control rats. The level of CK-MB and LDH was significantly 
elevated (p<0.001) in diabetic rats as compared to sham control group. 
Remarkably, CK-MB and LDH level were elevated significantly (p<0.001) 
in diabetic I-R rats as compare to diabetic control rats. Naringin low 
and high dose   and reference drug  glibenclamide-treated rats CK-MB 
and LDH level was significantly (p<0.001) decreased as compared to 
the diabetic I-R control group. Naringin 50 mg/kg treated rats show 
significantly (p<0.001) decreased cholesterol and LDH level as compare 
to glibenclamide-treated rats (Table 1).
Effect of Naringin on biochemical estimations (TBARS, GSH, and 
SOD level)
TBARS activity significantly (p<0.001) increased and GSH and SOD 
level significantly (p<0.001) decreased in diabetic control rats and 
as compared to the sham control group. As similar manner, more 
potentially TBARS level significantly (p<0.001) increased and GSH and 
SOD activity significantly (p<0.05, p<0.001) decreased, respectively, in 
diabetic I-R control rats as compared to diabetic control rats. Naringin 
25 and 50 mg/kg, p.o. treated group showed significantly (p<0.001) 
decreased TBARS, GSH level, and SOD activity as compared to diabetic 
I-R. Glibenclamide-treated group showed significantly (p<0.001) 
decreased GSH level and SOD activity as compared to diabetic I-R. 
Naringin 50 mg/kg treated rats show significantly (p<0.001) decreased 
TBARS, GSH level, and SOD activity as compared to glibenclamide-
treated rats (Table 2).
Effect of Naringin on hemodynamic evaluation
A significant (p<0.001) decrease in arterial pressure, significant 
(p<0.01) elevation in the heart rate (HR), and significant (p<0.001) 
elevation in the systolic arterial pressure (SAP) and diastolic arterial 
pressure (DAP) were observed in the diabetic control group when 
compared to sham control group. Significant (p<0.001) decreased in 
SAP, DAP, mean arterial pressure (MAP), and HR in diabetic I-R control 
rats as compared to diabetic control rats. On treatment with Naringin 
25 and 50 mg/kg significantly (p<0.001) restore AP as compared to 
diabetic I-R control group. Naringin 50 mg/kg treated rats significant 
(p<0.05) restore MAP and HR as compared to diabetic I-R control. 
Glibenclamide-treated rats show significant (p<0.001) restore AP, and 
also significant (p<0.01) restore the SAP, DAP, and MAP and significantly 
(p<0.05) restore the HR when compared to diabetic I-R group (Table 3).
Effect of Naringin on infarct size in rat heat
The infarct size was significantly increased diabetic control groups 
as compared to the sham control group. Infarct size was significantly 
increased diabetic I-R control groups as compared to the diabetic control 
group. Naringin (50 mg/kg, p.o.) and glibenclamide (20 mg/kg, p.o.) 
treated groups show significantly reduced the infarct size as compared 
to the diabetic I-R group (Fig. 4).
DISCUSSION
Diabetes mellitus is a rapidly growing health concern which causes 
several cardiovascular complications including ischemic heart disease, 
diabetic cardiomyopathy, and stroke [2,3]. The relative risk of ischemic 
heart disease in the diabetic population is more vulnerable compare 
that in the non-diabetic population [5]. The enhanced susceptibility 
is partially due to an associated metabolic disorder characterized by 
high blood glucose, insulin resistance, and dyslipidemia in patients 
with diabetic, which aggravated myocardial injury after myocardial 
ischemia-reperfusion [3,16]. The proposed model combination of HFD 
with a low dose of STZ-treated rat after that performed myocardial 
ischemic reperfusion (I-R) injury-induced damage in diabetes animals; 
it is surgical occlusion of coronary artery followed by reperfusion 
more closely to the real clinical setting. Recently, tend to focus on; 
search for new cardioprotective molecules have targeted as well as 
less complication in therapy. In this contest, the present study was 
undertaken to explore the cardioprotective effect of Naringin on 
ischemia-reperfusion injury in a diabetic rat model.
In the study, animal treated with HFD-STZ increases feed intake, water 
intake, and body weight was found to be significantly elevated, due to 
increased intake of feed. Linked with weight gain in a hyperglycemic 
state, glucose from the blood cannot enter the cells due to an abnormality 
of diabetes associated dysfunction with that body cannot convert the 
energy from food this condition feel lack of energy and causes an increase 
in hunger [18]. Increase in body weight and fat deposition is the chief 
indicators for the gradual progress of metabolic abnormalities and onset 
of obesity. Naringin-treated rats reduced and maintained feed intake, 
water intake, and body weight as compared to diabetic I-R control rats’ 
Fig. 1: Effect of Naringin on body weight. Value is expressed as 
mean±SEM. n=6; (a) *(p<0.05), ***(p<0.001) versus sham control 
group; (b) *(p<0.05), **(p<0.01), ***(p<0.001) versus diabetic I-R 
control group (One-way ANOVA followed by Tukey’s test)
Fig. 2: Effect of Naringin on water intake.
Value is expressed as mean±SEM. n=6; (a) *(p<0.05), ***(p<0.001) 
versus sham control group; (b) *(p<0.05), **(p<0.01), 
***(p<0.001) versus diabetic I-R control group (One-way ANOVA 
followed by Tukey’s test)
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results are in agreement with other experimental studies [19].
Various studies have reported that I-R injury sequence results in 
the generation of free radicals in the myocardium [5,7]. Ischemia 
reduced the activity of cellular defense systems against free radicals 
and reperfusion or restoration of oxygen further disturbs the delicate 
balance of oxidants/antioxidants and generates a burst of free radicals 
in the tissue [20]. Numerous studies suggested that increased oxidative 
stress, generation of reactive oxygen species (ROS), and imbalance in 
antioxidant and oxidant contribute to myocardial tissue injury which 
explains the decreased in heart weight due to myocardial loss [6,21]. 
The oxidative indicators GSH and SOD involved in heart disease have 
been previously reported [22]. Diabetic heart accelerates myocardial 
oxidative stress and subsequently aggravates heart damage and 
secondary to lead ischemia-reperfusion injury [5]. Hyperglycemia 
decreased the antioxidant capacity by reducing SOD and GSH 
activities [23]. We have observed decreased GSH and SOD level in the 
study group treated with a combination of HFD and a low dose of STZ 
plus I-R injury. In addition, HFD-STZ rats significantly increased the 
cardiac damaged enzymes level (CK-MB and LDH) possible indication 
of the increased severity of myocardial damage. It has been shown 
that the enhancement of CK-MB level and LDH attributed to the 
overproduction of free radicals and cell membrane injury that might 
have led to the release of cardiac toxic biomarkers [24]. Naringin 
Table 1: Effect of Naringin on blood parameters (glucose and cholesterol, CK-MB, and LDH)
Group Glucose Cholesterol CK-MB LDH
Sham 88.3±3.28 60.3±2.51 65.17±1.78 112.5±2.23
DIB control 331.0±7.49a*** 180.0±2.38a*** 87.33±3.69a*** 573±2.99a***
DIB I-R control 330.1±7.61 181.8±2.60 121.20±2.21b*** 810±2.94b***
NIR 25 mg/kg 170.0±8.66c*** 113.0±1.75c*** 76.17±1.30c*** 309.7±3.44c***
NIR 50 mg/kg 105.5±2.58c*** 80.3±3.79c***, d*** 68.67±2.23c*** 243.3±2.78c***, d***
GL 20 mg/kg 91.5±2.05c*** 176.7±1.36 74±0.89c*** 429.3±5.19c***
Values are expressed as mean±SEM. n=6; (a) ***(p<0.001) versus sham control; (b) ***(p<0.001) versus diabetic control group; (c) ***(p<0.001) versus diabetic I-R 
control group; (d) ***(p<0.001) versus glibenclamide 20 mg/kg (One-way ANOVA followed by Tukey’s test). CK-MB: Creatine kinase-muscle/brain, LDH: Lactate 
dehydrogenase
Table 2: Effect of Naringin on TBARS, GSH, and SOD level
Group TBARS GSH SOD
Sham 5.90±0.16 15.45±0.87 9.63±0.27
DIB control 21.93±0.37a*** 5.48±0.37a*** 4.32±0.11a***
DIB I-R control 31.81±0.16b*** 2.84±0.53b* 2.78±0.28b***
NIR 25 mg/kg 12.87±0.15c***, d*** 6.59±0.47c*** 5.26±0.08c***
NIR 50 mg/kg 11.65±0.90c***, d*** 14.73±0.56c*** , d*** 14.45±0.13c***, d***
GL 20 mg/kg 27.60±0.46 10.17±0.22c*** 6.93±0.19c***
Values are expressed as mean±SEM. n=6; (a) ***(P<0.001) versus sham control; (b) *(p<0.05) ***(p<0.001) versus diabetic control group; (c) ***(p<0.001) versus 
diabetic I-R control group; (d) ***(p<0.001) versus glibenclamide 20 mg/kg (One-way ANOVA followed by Tukey’s test). GSH: Glutathione, SOD: Superoxide dismutase
Table 3: Effect of Naringin on hemodynamic parameters
Groups AP SAP DAP MAP HR
Sham 115.7±1.65 124.3±1.36 84.67±1.09 97.88±1.46 426.2±1.14
DIB control 88.33±4.56a*** 140.5±1.40a*** 106.5±1.85a*** 117.5±1.86a*** 430.7±1.55a**
DIB I-R control 85.50±2.49 117.3±2.51b*** 77.83±1.86b*** 91.52±2.55b*** 415.3±1.15b***
NIR 25 mg/kg 104.0±3.05c*** 118.1±0.97 78.50±2.33 91.7±1.03 411.3±0.39
NIR 50 mg/kg 109.2±1.31c*** 121.1±0.68 82.25±0.92 95±0.98c* 421.8±0.49c*
GL 20 mg/kg 114.4±2.08c*** 123.6±0.57c** 83.16±0.69c** 96.64±0.78c** 422.1±2.06c*
Values are expressed as mean±SEM. n=6; (a) **(p<0.01), ***(p<0.001) versus sham control; (b) ***(p<0.001) versus diabetic control group; (c) *(p<0.05), **(p<0.01), 
***(p<0.001) versus diabetic I-R control group (One-way ANOVA followed by Tukey’s test). AP: Arterial pressure, SAP: Systolic arterial pressure, DAP: Diastolic arterial 
pressure, MAP: Mean arterial pressure, HR: Heart rate
Fig. 3: Effect of Naringin on feed intake.  Value is expressed as 
mean±SEM. n=6; (a) *(p<0.05), ***(p<0.001) versus sham control 
group; (b) *(p<0.05), **(p<0.01), ***(p<0.001) versus diabetic I-R 
control group (One-way ANOVA followed by Tukey’s test) Fig. 4: Effect of Naringin on infarct size in rat heart
234
Asian J Pharm Clin Res, Vol 12, Issue 3, 2019, 230-234
 Kumari and Kushwah 
activates AMP-activated protein kinase and hypolipidemic effect due 
to reducing the HMG-CoA reductase [9,10]. Feeding Naringin could 
downregulate the expression of gluconeogenic enzymes and result 
in lower blood glucose concentration [19]. Reduction of glucose level 
and cholesterol level in Naringin treatment confirms in the study. In 
agreement with these reports, treatment with Naringin significantly 
increased the activities of SOD and GSH and decreased the levels 
of MDA in heart and reduced CK-MB and LDH levels were reverted 
to normal which shows the protective effect of Naringin through 
maintenance of cell integrity and prevented cell injury and protect the 
myocardium. LDH level in Naringin-treated groups shown its potential 
to reduce oxidative, intracellular Ca2+ overload, inflammation, and 
hyperglycemia-induced ischemia-reperfusion injury and our results are 
in accordance with other experimental reports [25]. Observed that in 
Naringin treatment preserve near to normal heart muscle architecture, 
and reduced to infarct size. The data showed that Naringin is capable of 
limiting infarct size when administered before the onset of ischemia-
reperfusion and has shown cardioprotection in diabetes-induced 
myocardial I-R injury. Hyperglycemia condition associated with I-R, 
potentiate ROS generation increased the HR responsible for increased 
myocardial oxygen consumption and demand which leads to ischemic 
necrosis of the myocardium in animal [26,27]. Naringin treatment will 
help to preserve near normal heart functions, these were reflected by 
near normal the underlying the cardioprotective mechanisms effects of 
Naringin against diabetic IR-induced abnormality. There is evidence for 
an association between high dietary intakes of Naringin reduction of 
cardiac damage.
CONCLUSION
Therefore, the present study suggests a protective effect of Naringin at 
a higher dose on HFD-STZ-induced diabetes with myocardial ischemic 
reperfusion injury in rats. Naringin 50 mg/kg shown protected 
significantly for all parameters and it has a best effective dose. Further, 
we have concluded that Naringin at higher dose level effectively reduced 
the body weight it also reduced the blood glucose level and cholesterol 
level and showed a significant result in biochemical parameters, which 
effectively reduced the lipid peroxidation level and increased the 
GSH and SOD level and also shown significant result in hemodynamic 
parameters, MAP and HR. Naringin pre-treatment also reduced the 
myocardial infarction percentage and damage.
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